Search

Your search keyword '"ter Elst, Arja"' showing total 217 results

Search Constraints

Start Over You searched for: Author "ter Elst, Arja" Remove constraint Author: "ter Elst, Arja"
217 results on '"ter Elst, Arja"'

Search Results

1. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

3. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting

4. Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study

5. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

6. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

8. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands:interlaboratory variation in the primary diagnostic and recurrent setting

9. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting

10. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

11. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics

13. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material

22. Data from VEGFC Antibody Therapy Drives Differentiation of AML

25. Supplementary Table 3 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

28. Supplementary Table 2 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

29. Supplementary Figure 3 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

31. Supplementary Figure 2 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

32. Supplementary Figure 1 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

33. Supplementary Table 1 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

34. Supplementary Table 4 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

35. Supplementary Figure 4 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

36. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC:Results from the phase 2 multicenter POSITION20 trial

37. High Dose Osimertinib in Patients with Advanced Stage EGFR Exon 20 Mutation-Positive NSCLC: Results from the Phase 2 Multicenter POSITION20 Trial

39. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

41. Multicenter comparison of Molecular Tumor Boards in the Netherlands: definition, composition, methods and targeted therapy recommendations

43. Multicenter Comparison of Molecular Tumor Boards in The Netherlands:Definition, Composition, Methods, and Targeted Therapy Recommendations

44. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

45. Abstract 4335: Clinical value of EGFR gene amplifications detected using amplicon based targeted next generation sequencing data in lung adenocarcinoma patients

46. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation

48. Modeling of drug-protein interactions to support clinical decision making for therapy-resistant EGFR or ALK-positive non-small cell lung carcinoma

50. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics

Catalog

Books, media, physical & digital resources